First robotic-guided lung ablation cases commence

Creo Medical Group PLC

15 January 2025

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

First robotic-guided lung ablation cases commence

as part of Intuitive collaboration agreement

Robotic-guided microwave ablation of cancerous lung tissue now being undertaken at two UK sites

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the first robotic-guided microwave ablation of cancerous lung tissue cases have commenced at a leading UK hospital (the "Hospital").

As announced in July 2024, the Company amended its multi-year collaboration with Intuitive and this latest robotic-guided microwave ablation procedure for lung cancer is the first clinical case using Intuitive's Ion Endoluminal System and Creo's MicroBlate™ Flex ablation device to take place under the amended terms of the agreement at the Hospital.

The Hospital is now the second site to have performed microwave ablation procedures for lung cancer. The first UK site to perform such procedures was the Royal Brompton Hospital as part of an ongoing clinical study¹ conducted by Professor Shah.

The Pioneer Programme will continue to roll-out throughout 2025 to support the collection of clinical evidence ahead of the sites entering a commercial phase, and the Company expects the number of procedures performed to grow in the current year.

Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted that this first clinical site under the Pioneer Programme, representing a second UK clinical site, has started clinical practice and successfully completed their first robotic-guided lung cancer ablation procedure using Creo's MicroBlate Flex alongside Intuitive's Ion Endoluminal System. With both the clinical study at the Royal Brompton and this site as part of the clinical Pioneer Programme, we now have two UK hospitals undertaking these procedures. These sites, under the amended collaboration agreement with Intuitive, will provide us with the clinical evidence needed to support the wider commercialisation of the MicroBlate Flex device. We look forward to updating shareholders on our progress."

¹ Bronchoscopic Microwave Ablation of Lung Tissue - Full Text View - ClinicalTrials.gov

 For further information please contact: 

Creo Medical Group plc		www.creomedical.com
Richard Craven, Company Secretary		Via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)		[phone]
Stephen Keys / Camilla Hume / George Lawson (NOMAD)
Michael Johnson (Sales)
Deutsche Numis (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown		[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings Phillip Marriage	Mob: [phone] Mob: [phone]

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END